Germany's "National Decade Against Post-Infectious Diseases"

Possibly. Isatuximab wasn't mentioned explicitly, only her group.

Edit: speak of the devil



I feel like I'm missing something. Is Uplinza funding separate from the National Decade against Post-Infectious Diseases?

From the linked page:
In 2026, for example, a newly designed Phase II study on the efficacy and safety of the monoclonal antibody Uplizna will start.

From previous post:
For this reason, the initial research funding guidelines will not aim to promote individual therapies or specific drug candidates.
 
From reading in the other thread it seems like she wants to do cd20 as well as cd19 and cd38 maybe? I mean at least we'll get some really concrete answers on that and put the rituximab debate to bed at last if they do that.
If uses proper methodology.
IIRC her team has had a history of spinning negative results as positive so not holding my breath.
 
Back
Top Bottom